Quest Laboratories Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Circuit Breaker Trigger

On 27 Feb 2026, Quest Laboratories Ltd’s stock price dropped by ₹6.30, closing at ₹119.95, which was the lower circuit price band for the day. The stock’s price band was set at 5%, and the maximum permissible daily loss was fully realised. The highest price recorded during the session was ₹122.50, but persistent selling pressure pushed the price down to the floor limit. This triggered the lower circuit breaker, halting further declines and trading at this price for the remainder of the day.

Volume and Liquidity Analysis

The total traded volume stood at 0.252 lakh shares, translating to a turnover of ₹0.30 crore. While the stock remains liquid enough for trade sizes of approximately ₹0.01 crore based on 2% of the five-day average traded value, the delivery volume on 26 Feb 2026 was only 36,000 shares, marking a significant 34.5% decline compared to the five-day average delivery volume. This drop in investor participation suggests a cautious stance among shareholders amid the recent volatility.

Comparative Performance and Moving Averages

Quest Laboratories Ltd underperformed its Pharmaceuticals & Biotechnology sector, which declined by 0.53% on the same day, and the Sensex, which fell by 0.70%. Despite the sharp fall, the stock’s price remains above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating that the longer-term trend is still intact. However, it closed below its 5-day moving average, signalling short-term weakness and potential further downside pressure if selling persists.

Market Capitalisation and Sector Context

Quest Laboratories Ltd is classified as a micro-cap stock with a market capitalisation of ₹207 crore. Operating within the Pharmaceuticals & Biotechnology sector, the company faces stiff competition and sectoral volatility, which can amplify price swings. The sector’s modest decline on the day contrasts with the stock’s sharper fall, highlighting company-specific factors or investor sentiment driving the sell-off.

Investor Sentiment and Panic Selling

The sharp fall to the lower circuit limit is indicative of panic selling, where investors rush to exit positions amid uncertainty or negative triggers. The unfilled supply at the lower price levels suggests that sellers overwhelmed buyers, leading to a liquidity imbalance. This scenario often results in circuit breakers being hit to prevent disorderly market behaviour and provide a cooling-off period.

Mojo Score and Analyst Ratings

Despite the recent price weakness, Quest Laboratories Ltd holds a robust Mojo Score of 81.0, categorised as a Strong Buy by MarketsMOJO. This rating was upgraded from Buy on 16 Feb 2026, reflecting improved fundamentals and positive outlook. The company’s Market Cap Grade is 4, indicating moderate size within its category. Investors should weigh the current technical weakness against the favourable long-term assessment.

Technical Outlook and Moving Average Implications

The stock’s position above its medium and long-term moving averages suggests underlying strength, but the breach below the 5-day moving average signals short-term caution. If the stock fails to recover above this level in the coming sessions, it may face further downward pressure. Conversely, a rebound from the lower circuit could attract bargain hunters, especially given the strong Mojo Grade and recent upgrade.

Implications for Investors

For investors, the lower circuit hit serves as a cautionary signal. While the strong Mojo Grade and recent upgrade suggest positive fundamentals, the immediate technical weakness and heavy selling pressure warrant close monitoring. Investors should consider their risk tolerance and investment horizon before making decisions. Those with a long-term view may find the current price levels attractive for accumulation, whereas short-term traders might prefer to wait for confirmation of a trend reversal.

Conclusion

Quest Laboratories Ltd’s plunge to the lower circuit on 27 Feb 2026 underscores the volatility micro-cap stocks can experience, especially in sensitive sectors like Pharmaceuticals & Biotechnology. The combination of panic selling, unfilled supply, and reduced investor participation contributed to the sharp decline. However, the company’s strong Mojo Score and recent rating upgrade provide a counterbalance, suggesting that the current weakness could be temporary. Investors should remain vigilant and analyse both technical signals and fundamental data before acting.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today